No matches

4 search results for: heterogeneity

<b>Heterogeneity</b> and Unpredictability: Challenges With the Diagnosis and Evaluation of CSU

Dermatology

Heterogeneity and Unpredictability: Challenges With the Diagnosis and Evaluation of CSU

10 min

expert video

In this video from EADV 2025, Dr. Netchiporouk discusses the clinical features, diagnosis, and burden of CSU

Dermatology

Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

45 min

expert video

Professors Metz, Netchiporouk, and Hawkes discuss the clinical features, pathophysiology, and therapeutic landscape of CSU, at EADV 2025.

On Demand

Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

Experience this engaging presentation by Professors Martin Metz, Elena Netchiporouk, and Jason Hawkes to explore emerging therapies for chronic spontaneous urticaria.

Congress

September

2025

Congress

ADVENT at EADV 2025

Join leading dermatologists for educational symposia on atopic dermatitis, bullous pemphigoid, and chronic spontaneous urticaria at the EADV congress in Paris, France.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: TaiwanChange country/region